314267-57-7

JNJ 17029259 is an orally active and selective VEGF-R2 kinase inhibitor. JNJ 17029259 inhibits VEGF-mediated signal transduction. JNJ 17029259 has anti-angiogenic activity[1][2].

[1] Mohammed S. I. Makki, et al. Fluorine Substituted 1,2,4-Triazinones as Potential Anti-HIV-1 and CDK2 Inhibitors. Journal of Chemistry. 2014. Article ID 430573.
[2] Reuman M, et al. Scalable synthesis of the VEGF-R2 kinase inhibitor JNJ-17029259 using ultrasound-mediated addition of MeLi-CeCl3 to a nitrile. J Org Chem. 2008 Feb 1;73(3):1121-3. DOI:10.1021/jo7021372